Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ATHE 
Alterity Therapeutics Ltd (ATHE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/11/2025: ATHE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -54.46% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 33.98M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 855104 | Beta 0.48 | 52 Weeks Range 1.00 - 5.87 | Updated Date 04/1/2025 |
52 Weeks Range 1.00 - 5.87 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.51 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -469.68% |
Management Effectiveness
Return on Assets (TTM) -78.37% | Return on Equity (TTM) -155.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 29438725 | Price to Sales(TTM) 9.12 |
Enterprise Value 29438725 | Price to Sales(TTM) 9.12 | ||
Enterprise Value to Revenue 113.99 | Enterprise Value to EBITDA 0.75 | Shares Outstanding 10685800 | Shares Floating 4745527004 |
Shares Outstanding 10685800 | Shares Floating 4745527004 | ||
Percent Insiders - | Percent Institutions 1.13 |
Analyst Ratings
Rating 4.5 | Target Price 9 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Alterity Therapeutics Ltd
Company Overview
History and Background
Alterity Therapeutics Ltd (formerly Prana Biotechnology) was founded in 1997. It is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases. Significant milestones include the development of PBT434 and progress in clinical trials.
Core Business Areas
- Neurodegenerative Disease Therapeutics: Developing treatments targeting underlying mechanisms of neurodegenerative diseases, particularly Parkinson's and Alzheimer's diseases.
- Drug Development: Discovering and developing novel small molecule therapeutics.
Leadership and Structure
The leadership team consists of a CEO, Chief Medical Officer, and other executives overseeing research, development, and operations. The organizational structure is typical of a biotech company with distinct R&D, clinical, and business development departments.
Top Products and Market Share
Key Offerings
- PBT434: PBT434 is Alterity's lead drug candidate, a small molecule designed to inhibit the aggregation of alpha-synuclein, a protein implicated in Parkinson's disease and other synucleinopathies. Currently in clinical trials. Market share is not yet applicable as it is not yet approved. Competitors: Denali Therapeutics, Biogen, Roche
Market Dynamics
Industry Overview
The neurodegenerative disease market is large and growing, driven by aging populations and a lack of effective treatments. There is intense competition for new therapies.
Positioning
Alterity is positioned as a developer of novel therapies targeting specific disease mechanisms. Their competitive advantage lies in their unique approach to inhibiting alpha-synuclein aggregation with PBT434.
Total Addressable Market (TAM)
The TAM for Parkinson's disease therapeutics is estimated to be over $5 billion. Alterity is positioned to capture a share of this market if PBT434 proves effective.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (PBT434)
- Targeting a significant unmet medical need
- Experienced management team
Weaknesses
- Early stage of development
- High risk of clinical trial failure
- Limited financial resources
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into other neurodegenerative diseases
Threats
- Competition from other companies
- Regulatory hurdles
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- SNCA
- BIIB
- ROSY
Competitive Landscape
Alterity faces competition from established pharmaceutical companies with greater resources and more advanced clinical programs. Their advantage lies in a novel mechanism of action. SNCA, BIIB and ROSY compete in similar diseases that Alterity is trying to treat
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Due to the stage of Alterity's lead product, substantial revenue growth is contingent on successful clinical trials and regulatory approval.
Future Projections: Future growth projections are highly dependent on the success of PBT434's clinical trials.
Recent Initiatives: Recent initiatives include ongoing clinical trials of PBT434 and efforts to secure funding.
Summary
Alterity Therapeutics is a biotechnology company focused on developing treatments for neurodegenerative diseases, primarily Parkinson's. Their lead candidate, PBT434, is in clinical trials. The company's success hinges on the outcome of these trials and its ability to secure funding. Key risks include clinical trial failures and competition. Alterity has a novel approach to inhibiting alpha-synuclein aggregation.
Similar Companies
BIIB
Biogen Inc
BIIB
Biogen Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. This information is subject to change and may not be complete or accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alterity Therapeutics Ltd
Exchange NASDAQ | Headquaters Melbourne, VIC, Australia | ||
IPO Launch date 2002-09-05 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | Website https://alteritytherapeutics.com |
Full time employees 10 | Website https://alteritytherapeutics.com | ||
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.